Röggla M, Wagner A, Brunner C, Röggla G
Department of Emergency Medicine, University of Vienna.
Wien Klin Wochenschr. 1996;108(11):330-3.
The thoracic vent is a new minimally invasive device for the treatment of spontaneous and iatrogenic pneumothorax. It consists of a polyurethane catheter connected to a plastic chamber containing a one-way valve. As there is no need to connect the thoracic vent to an underwater seal device, immobilization and hospitalization can be avoided. So far the performance of the thoracic vent has been evaluated only in patients without pleural effusions and without signs of tension pneumothorax. Hence, we have performed a randomized study comparing the treatment of pneumothorax by means of the thoracic vent versus conventional intercostal tube drainage in 30 patients, including some with tension pneumothorax. 17 patients were treated with the thoracic vent, 13 with conventional intercostal tube drainage. We found no significant differences in the rate of reexpansion and rate of complications between the group treated with the thoracic vent and the group treated with intercostal tube drainage, but the patients treated with the thoracic vent needed significantly less analgesics. 70% of the patients treated with the thoracic vent were successfully managed on an outpatient basis. All patients treated with intercostal tube drainage were hospitalised; duration of inpatient-therapy was 8 +/- 6.2 days (mean +/- SD).
胸腔通气装置是一种用于治疗自发性和医源性气胸的新型微创设备。它由一根聚氨酯导管连接到一个装有单向阀的塑料腔室组成。由于无需将胸腔通气装置连接到水封装置，因此可以避免固定和住院。到目前为止，胸腔通气装置的性能仅在没有胸腔积液且没有张力性气胸迹象的患者中进行了评估。因此，我们进行了一项随机研究，比较了30例患者（包括一些张力性气胸患者）使用胸腔通气装置与传统肋间导管引流治疗气胸的效果。17例患者接受胸腔通气装置治疗，13例接受传统肋间导管引流治疗。我们发现，胸腔通气装置治疗组和肋间导管引流治疗组在肺复张率和并发症发生率方面没有显著差异，但使用胸腔通气装置治疗的患者所需的镇痛药明显较少。70%接受胸腔通气装置治疗的患者在门诊成功治愈。所有接受肋间导管引流治疗的患者均住院治疗；住院治疗时间为8±6.2天（平均值±标准差）。
